Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Thymopentin; Drug
Lead sponsor: Immunobiology Research Institute; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Annandale, New Jersey

Conditions: Inflammation, HIV Infection, Cardiovascular Disease
Interventions: VB-201, Placebo; Drug
Lead sponsor: Priscilla Hsue, MD; Other
Eligibility: 40 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus
Interventions: Social Network, Brief HIV Prevention Counseling; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 16 Years and older · Male only
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio • Milwaukee, Wisconsin

Conditions: Acquired Immunodeficiency Syndrome, Mycobacterium Avium-Intracellulare Infection
Interventions: Interleukin-12; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hormonal Contraception
Interventions: Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Papillomatosis, HIV Infections
Interventions: Interferon-alpha, placebo; Drug · Other
Lead sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more

Conditions: HIV-1 Infection
Interventions: Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more

Conditions: HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 2
States / cities: St Louis, Missouri • Seattle, Washington

Conditions: HIV Infection
Interventions: Tenofovir DF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: GSK2248761 formulation 1, GSK2248761 reference formulation, GSK2248761 formulation 3, GSK2248761 formulation 2 or 4; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Food Insecurities, Cardiometabolic Comorbidities, HIV, PreDiabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions: weCare/Secure, Usual Care; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: HIV
Interventions: Truvada, Combivir, Trizivir; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus, HIV
Interventions: PositiveLinks for Youth Smartphone App; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 29 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Human Immunodeficiency Virus, Hepatitis C
Interventions: EBR/GZR; Drug
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: ABC/DTG/3TC FDC tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Efavirenz (EFV), Truvada; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Human Immunodeficiency Virus
Interventions: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Human Immunodeficiency Virus Infections
Interventions: Efavirenz 600mg, Boosted Lexiva; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: HIV Infection, Alcohol Use, Bone Disease, Substance-Related Disorders
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Sexually Transmitted Infection
Interventions: PrEPwise, Usual care; Behavioral · Other
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: HIV Infection
Interventions: ADMVA; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 13 more

Search by objective public record fields.

Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

Increasing PrEP Use in High-Risk Social Networks of African-American MSM in Underserved Low-Risk Cities

Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection

Contraceptive Hormones, Immunity, and Microbiome Evaluation

Treatment of Oral Warts in HIV+ Patients

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Tenofovir Disoproxil Fumarate to Treat Pediatric HIV

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

Human Immunodeficiency Virus (HIV) Food Insecurities

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

PositiveLinks for Youth (PL4Y) for Texas

Impact of Hepatitis C Therapy and Bone Health

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

Biomarkers for Event-driven PrEP Adherence

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort

PrEPwise Pilot Among Black Women in Eastern Virginia

Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC